Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects
- PMID: 12748879
- DOI: 10.1007/s102380300015
Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects
Abstract
Platelets and monocytes are involved in atherothrombosis via tissue factor expression. Moreover, they are activated in hypercholesterolemia, a classic risk factor for atherothrombosis. Cholesterol-lowering drugs (statins) reduce cardiovascular risk either by decreasing cholesterol or non-lipidic actions, such as platelet and monocyte activity. The aim of our study was to evaluate the effect of several statins on platelet and monocyte activity in hypercholesterolemic subjects. Platelet activity (P-selectin, cytofluorimetric detection), tissue factor levels (ELISA) and activity (detected in whole blood and cellular preparations by a specific clotting assay) were measured in hypercholesterolemic subjects (41 males, 23 females, aged 34-65 years, total cholesterol 6.86+/-0.60 mmol/l) treated with atorvastatin 10 mg, simvastatin 20 mg, fluvastatin 40 mg, or pravastatin 40 mg for 6 weeks. P-selectin and tissue factor expression in whole blood and isolated cells were increased in hypercholesterolemic subjects with respect to controls (all P<0.001). Simvastatin, atorvastatin, and fluvastatin reduced monocyte procoagulant activity in whole blood and P-selectin (P<0.01). Tissue factor antigen and activity in isolated cells were further reduced (all P<0.05) independently of cholesterol lowering. Pravastatin decreased tissue factor expression in whole blood in direct relationship to reduction of P-sel and cholesterol (P<0.05). Our data show a different impact of several statins on monocyte tissue factor expression in whole blood, suggesting a possible role of decreased platelet activity and a direct action on monocytes. In contrast, pravastatin decreased monocyte procoagulant activity with relation to cholesteroldependent modifications of platelet function.
Similar articles
-
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.Nutr Metab Cardiovasc Dis. 2001 Dec;11(6):378-87. Nutr Metab Cardiovasc Dis. 2001. PMID: 12055702 Clinical Trial.
-
Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects.Int J Cardiol. 2004 Jun;95(2-3):269-74. doi: 10.1016/j.ijcard.2003.08.003. Int J Cardiol. 2004. PMID: 15193831 Clinical Trial.
-
[Effect of platelet on procoagulant activity of monocyte].Zhonghua Xue Ye Xue Za Zhi. 2001 Sep;22(9):478-80. Zhonghua Xue Ye Xue Za Zhi. 2001. PMID: 11758230 Chinese.
-
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.Eur J Med Res. 2004 Jan 26;9(1):1-17. Eur J Med Res. 2004. PMID: 14766335 Review.
-
The role of platelets in decrypting monocyte tissue factor.Dis Mon. 2003 Jan;49(1):7-13. doi: 10.1053/shem.2001.29508b. Dis Mon. 2003. PMID: 12525824 Review.
Cited by
-
Fluvastatin for lowering lipids.Cochrane Database Syst Rev. 2018 Mar 6;3(3):CD012282. doi: 10.1002/14651858.CD012282.pub2. Cochrane Database Syst Rev. 2018. PMID: 29508377 Free PMC article.
-
Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.J Thromb Haemost. 2021 Jul;19(7):1709-1717. doi: 10.1111/jth.15282. Epub 2021 Apr 12. J Thromb Haemost. 2021. PMID: 33638931 Free PMC article. Clinical Trial.
-
Lipid-lowering efficacy of atorvastatin.Cochrane Database Syst Rev. 2015 Mar 12;2015(3):CD008226. doi: 10.1002/14651858.CD008226.pub3. Cochrane Database Syst Rev. 2015. PMID: 25760954 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources